Cardisure Flavoured Tablets for Dogs (1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg)

Country: New Zealand

Bahasa: Inggeris

Sumber: Ministry for Primary Industries

Bahan aktif:

pimobendan

Boleh didapati daripada:

Dechra Veterinary Products NZ Limited

Komposisi:

pimobendan 5.73 g/kg

Kawasan terapeutik:

Cardiovascular agent

Tarikh kebenaran:

2018-05-25

Ciri produk

PRODUCT NAME:
CARDISURE FLAVOURED TABLETS FOR DOGS
COMPANY
Eurovet_Dechra Veterinary Products
PACK SIZES:
All tablet strengths (1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg)
DATE:
08
th
February 2024
Text above this line or in italics between parallel lines is not
included in the label copy.
Page 1 of 5
All tablet strengths – CARTON FRONT PANEL
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
CARDISURE
FLAVOURED 1.25 [2.5, 5, 10]MG TABLETS FOR
DOGS
ACTIVE CONSTITUENT: Each tablet contains 1.25 [2.5, 5.0, 10.0] mg
pimobendan
FOR THE TREATMENT OF CANINE CONGESTIVE HEART FAILURE ORIGINATING FROM
VALVULAR
INSUFFICIENCY (MITRAL AND/OR TRICUSPID REGURGITATION) OR DILATED
CARDIOMYOPATHY (DCM).
FOR THE TREATMENT OF PRECLINICAL DCM IN LARGE BREEDS. WHEN USED IN
CASES OF PRECLINICAL
DCM IN LARGE BREED DOGS, PIMOBENDAN SIGNIFICANTLY PROLONGED THE TIME
TO THE ONSET OF
CHF OR SUDDEN DEATH, AND ALSO RESULTED IN PROLONGATION OF THE TIME TO
DEATH DUE TO ALL
CAUSES.
DOBERMAN PINSCHER DOGS WITH PRECLINICAL DCM TREATED WITH PIMOBENDAN
ALSO
DEMONSTRATED A SIGNIFICANT REDUCTION IN LEFT VENTRICULAR INTERNAL
DIAMETER IN BOTH
SYSTOLE AND DIASTOLE (LVIDS/D) IN RESPONSE TO THERAPY.
CONTENTS
20, 25, 40, 50, 80, 100, 250 TABLETS
PRODUCT NAME:
CARDISURE FLAVOURED TABLETS FOR DOGS
COMPANY
Eurovet_Dechra Veterinary Products
PACK SIZES:
All tablet strengths (1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg)
DATE:
08
th
February 2024
Text above this line or in italics between parallel lines is not
included in the label copy.
Page 2 of 5
All tablet strengths – CARTON BACK PANEL
READ THE ENCLOSED LEAFLET FOR FULL INSTRUCTIONS
DIRECTIONS FOR USE:
DOSAGE AND ADMINISTRATION:
The tablets should be administered orally at a dose range of 0.1 mg to
0.3 mg pimobendan/kg
bodyweight twice daily. The ideal dose is 0.25 mg pimobendan/ kg
bodyweight twice daily,
administered 12 hours apart. Each dose should be administered on an
empty stomach, and at least
one hour before feeding.
The maintenance dose should be individually adjusted according t